Oligometastatic disease and remote stereotactic body ablative radiotherapy. Part III. Prostate cancer

This article is a continuation of the initial series of articles devoted to the current state of the issue of the role of remote stereotactic ablative radiotherapy of the body (RSABRT) in oligometastatic disease (OMD). In the first signal message on this problem (Vestnik of the Russian Scientific Center of Roentgenoradiology. 2023; 2023(3)), general issues related to the use of RSABRT in patients with OMD were highlighted. In subsequent publications, the current state of the issue of the implementation of RSABRT in the OMD of lung and breast cancer has already been assessed. In order to avoid any ambiguity in the definition of OMD in prostate cancer, which can occur both in hormone-sensitive tumors and in clinical practice in patients with castration-resistant prostate cancer, this article addresses issues related only to oligometastatic hormone-sensitive prostate cancer, namely, the biology, evidence, and controversies regarding synchronous de novo RSABRT of oligometastatic hormone-sensitive prostate cancer.